Cardiac effects of muscarinic receptor antagonists used for voiding dysfunction

Thorough QT study of the effect of fesoterodine on cardiac repolarization

(2011) B. Malhotra et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Drug- and non-drug-associated QT interval prolongation

(2010) Charlotte Van Noord et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

The Prognostic Significance of Heart Rate for Cardiovascular Disease and Hypertension

(2010) Trygve B. Tjugen et al.   CURRENT HYPERTENSION REPORTS

The effect of tolterodine 4 and 8 mg on the heart rate variability in healthy subjects

(2010) Maya Schiffers et al.   WORLD JOURNAL OF UROLOGY

Formulary Forum: Fesoterodine for the Treatment of Overactive Bladder

(2009) Maria Tzefos et al.   ANNALS OF PHARMACOTHERAPY

Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder

(2009) Karl-Erik Andersson et al.   BJU INTERNATIONAL

The Design and Development of Fesoterodine as a Prodrug of 5- Hydroxymethyl Tolterodine (5-HMT), the Active Metabolite of Tolterodine

(2009) B. Malhotra et al.   CURRENT MEDICINAL CHEMISTRY

Urodynamic Measurements by Radiotelemetry in Conscious, Freely Moving Beagle Dogs

(2009) Gerald P. McCafferty et al.   JOURNAL OF UROLOGY

QT prolongation and torsade de pointes associated with solifenacin in an 81-year-old woman

(2008) Hiroshi Asajima et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Slower Heart Rates for Healthy Hearts

(2008) Rakesh Gopinathannair et al.   Circulation-Arrhythmia and Electrophysiology

Cardiovascular Safety and Overall Tolerability of Solifenacin in Routine??Clinical Use

(2008) Martin C Michel et al.   DRUG SAFETY

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

(2008) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome

(2008) Martin C Michel   EXPERT OPINION ON PHARMACOTHERAPY

Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants ≥50 Years

(2008) Brian Olshansky et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS

Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial

(2008) Kim Fox et al.   LANCET